Michael speaks with Tim Wu, the Columbia law professor and author of The Age of Extraction, about how media and tech platforms learned to harvest our attention, why convenience is among the most powerful forces of our time, and what the easy option can take from us. They discuss:(00:00) Cold open(01:12) Selling attention, from 1833 to now(07:46) Why phones are changing human evolution(16:20) Why ads adapt to every backlash(18:00) Attention merchants vs. extractors(25:48) Easiest wins: the power of

Genmab and AbbVie's investigational frontline Epkinly (epcoritamab) combination cut progression-or-death hazard 51% versus R-CHOP in lymphoma patients with IPI scores of 3–5; it did not face Polivy's approved regimen. Vaxcyte's VAX-31 met its pivotal immune-response framework, with two serotypes clearing only a looser threshold against Merck's CAPVAXIVE—not proof of disease prevention. Deals span GE HealthCare–SOFIE and PET tracer FAPI-74, Shionogi–IntraBio and AQNEURSA in rare

👉 Quer receber os áudios todos os dias no seu WhatsApp? https://vedanta.com.br/podcast 🎓 Cursos Gratuitos e Turmas Regulares: https://vedanta.com.br/

He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.

What is the state of the debate over evolution and intelligent design in the UK? And how will Discovery Institute's new Cambridge initiative impact the debate going forward? On this ID The Future, host Andrew McDiarmid welcomes fellow Scotsman Dr. Alistair McKitterick, a Consulting Fellow at the Center for Science & Culture’s Whewell Center in Cambridge and a Program Director at London School of Theology. The pair will discuss how Alistair got interested in intelligent design, his work at the

Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicine.

Each week, join Editor-in-Chief Brad Maron, along with cohosts Mercedes Carnethon and Jane Wilcox for the new iteration of Circulation on the Run. This week, Brad and Merci welcome our own Jane Wilcox to discuss a new article type in Circulation: Clinical Problem-Solving. She also discusses her own Clinical Problem-Solving article "When VT Storm, PET Positivity, and a Negative Endomyocardial Biopsy Collide." Then Brad and Merci speak with Associate Editor Maria Kontaridis as she discusses her

🧠 JOIN THE GIANT'S SHOULDER FAMILYBecome a YouTube Member for exclusive episodes, early access + ad-free viewing 👇https://www.youtube.com/@thegiantsshoulder/joinAlexander Beiner is the writer who volunteered as a guinea pig for the world's first extended-state DMT trial. At Imperial College London, he was one of eleven people kept on a continuous DMT drip for thirty minutes. He is a co-Executive Director of Breaking Convention, Europe's largest psychedelic conference, and the author of

Bu bölümde, İngiltere MHRA'nın 29 Eylül 2026 tarihli DSI/2026/012 sayılı Cihaz Güvenliği Bilgisi'ni inceliyoruz. Kablosuz kardiyotokografi (CTG) izleme sistemlerinde tanımlanan sinyal karışması ve kesintisi risklerini ve bu durumun RF özellikli tıbbi cihaz üreticileri için pazar sonrası uyumluluk ve risk yönetimi açısından ne anlama geldiğini ele alıyoruz.Key Questions: - MHRA'nın kablosuz CTG sistemleri hakkındaki en son güvenlik uyarısı neleri içeriyor? - Sinyal karışması ve kesintisi riskleri

Den 29 september 2026 utfärdade Storbritanniens MHRA en säkerhetsinformation (DSI/2026/012) om riskerna med trådlösa kardiotokografi-system (CTG). I det här avsnittet analyseras de identifierade riskerna med signalöverhörning och signalbortfall och de åtgärder som krävs av vårdpersonal. Vi fokuserar på vad detta meddelande innebär för tillverkare av medicintekniska produkter när det gäller övervakning efter utsläppande på marknaden, riskhantering och uppdateringar av bruksanvisningar.Key

Neste episódio, analisamos a Informação de Segurança de Dispositivos (DSI/2026/012) da MHRA do Reino Unido, emitida em 29 de setembro de 2026, sobre os riscos associados aos sistemas de cardiotocografia (CTG) sem fio. Discutimos os perigos específicos de cruzamento e perda de sinal, as ações exigidas pela MHRA para os profissionais de saúde e, mais importante, detalhamos as implicações críticas para os fabricantes de dispositivos médicos. Apresentamos ações práticas que as equipes de regulamentação

Le 29 septembre 2026, la MHRA du Royaume-Uni a publié un avis de sécurité (DSI/2026/012) concernant les risques critiques des systèmes de cardiotocographie (CTG) sans fil, notamment le croisement de signaux et les pertes de signal. Cet épisode détaille les actions requises par la MHRA pour les professionnels de la santé et explore les implications plus larges pour les fabricants de dispositifs médicaux compatibles RF. Nous discutons des mesures proactives que les équipes réglementaires et qualité

इस एपिसोड में, हम 29 सितंबर, 2026 को जारी यूके MHRA की डिवाइस सुरक्षा सूचना (DSI/2026/012) पर चर्चा करते हैं, जो वायरलेस कार्डियोटोकोग्राफी (CTG) मॉनिटरिंग सिस्टम में सिग्नल क्रॉसओवर और ड्रॉपआउट के जोखिमों पर प्रकाश डालती है। हम बताते हैं कि यह निर्माताओं के लिए पोस्ट-मार्केट अनुपालन और जोखिम प्रबंधन के लिए क्या मायने रखता है, और नियामक टीमों को अपनी जोखिम फ़ाइलों, उपयोग के निर्देशों और निगरानी रणनीतियों की समीक्षा करने के लिए व्यावहारिक कदम प्रदान करते हैं।Key Questions: - MHRA ने वायरलेस

Trong tập này, chúng ta sẽ tìm hiểu sâu về Thông tin An toàn Thiết bị (DSI/2026/012) gần đây của MHRA Vương quốc Anh, được ban hành vào ngày 29 tháng 9 năm 2026, về các rủi ro của hệ thống theo dõi tim thai (CTG) không dây. Chúng ta sẽ phân tích các rủi ro cụ thể về giao thoa tín hiệu và mất tín hiệu, các hành động bắt buộc đối với các nhà cung cấp dịch vụ chăm sóc sức khỏe, và quan trọng nhất là những tác động sâu sắc đối với các nhà sản xuất thiết bị y tế hỗ trợ RF. Hãy lắng nghe để biết các bước

В этом выпуске мы анализируем Информационное сообщение о безопасности устройств MHRA (DSI/2026/012) от 29 сентября 2026 года, касающееся беспроводных кардиотокографических (КТГ) систем. Мы обсуждаем конкретные риски, такие как перекрестные помехи сигнала и его потеря, а также подробно рассматриваем обязательства производителей по постмаркетинговому надзору, обновлению файлов по управлению рисками и инструкций по применению для обеспечения безопасности пациентов.Key Questions: - Что такое

Pada tanggal 29 September 2026, MHRA Inggris mengeluarkan Informasi Keselamatan Perangkat (DSI/2026/012) yang membahas risiko keselamatan pada sistem kardiotokografi (CTG) nirkabel, termasuk sinyal bersilangan (signal crossover) dan sinyal terputus (signal dropouts). Episode ini menguraikan tindakan yang diwajibkan oleh MHRA bagi para profesional kesehatan dan mengeksplorasi implikasi pentingnya terhadap kepatuhan pasca-pemasaran, manajemen risiko, dan desain bagi produsen perangkat medis

In this episode of The BioHub Podcast, Ben sits down with Dr. Inder Kaul, Chief Medical Officer at Draig Therapeutics, to discuss the evolution of neuropsychiatric drug development and what it takes to translate novel neuroscience into meaningful medicines for patients.Inder brings decades of global clinical development experience, most recently playing a key role in the development of Cobenfy at Karuna Therapeutics and Bristol Myers Squibb - one of the most significant advances in schizophrenia

Lilly's retatrutide detail reveals that adverse-event discontinuations peaked below the top dose, while Jaypirca gains first-line CLL and SLL approval for adults without a known 17p deletion. Novartis agrees to $575 million upfront for Abogen's autoimmune RNA program, and Sanofi-Regeneron expands its long-acting antibody partnership. Ovarian-cancer datasets, Mirum's hepatitis D results and uniQure's Huntington's filing show why patient populations and control groups matter. CMS

Jason Hafler shares an overview of the corporate side of the venture world. He describes the unique value that he believes a corporate based VC can bring to the companies it invests in. Plus, his description of cases where investments might ultimately be a good fit for BD and/or M&A within the company, and why an investment might ultimately land at a different suitor.

Dr. Don and Professor Ben talk about the risks Dr. Don - risky ☣️ Professor Ben - risky ☣️ Fulminant Bacillus cereus food poisoning with fatal multi-organ failure | BMJ Case Reports Predictive Model for Growth of Bacillus cereus at Temperatures Applicable to Cooling of Cooked Pasta - Juneja - 2019 - Journal of Food Science - Wiley Online Library Heat-stable toxin production by strains of Bacillus cereus, Bacillus firmus, Bacillus megaterium, Bacillus simplex and Bacillus licheniformis | FEMS